Daniel D. Von Hoff, M.D., is currently Professor of Medicine, Pathology, Molecular and Cellular Biology, Director of the Arizona Health Sciences Center's Cancer Therapeutics Program and Director of Translational Research at the Translational Genomics Research Institute (TGen). He is also Chief Scientific Officer for US Oncology.

Dr. Von Hoff has published more than 503 papers, 126 book chapters, and more than 844 abstracts. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder and board member of ILEX(tm) Oncology, Inc. (ILXO, Nasdaq). He is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.